Återgå till huvudnavigering Återgå till sök Gå direkt till huvudinnehållet

Preventing Introduction of Livestock Associated MRSA in a Pig Population - Benefits, Costs, and Knowledge Gaps from the Swedish Perspective

  • Sören Höjgård
  • , Olov Aspevall
  • , Björn Bengtsson
  • , Sara Haeggman
  • , Maria Lindberg
  • , Svante Nilsson
  • , Kristina Mieziewska
  • , Helle Ericsson Unnerstad
  • , Diana Viske
  • , Helene Wahlström

Publikation: Bidrag till tidskriftArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

Antibiotic resistance is a growing concern in human, as well as in veterinary medicine. Part of the problem concerns how to respond to the risk presented by animal reservoirs of resistant bacteria with the potential of spreading to humans. One example is livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA). In countries where LA-MRSA is endemic in the pig population, people in contact with pigs have a higher risk of being colonised with LA-MRSA, and persons from this group are subjected to precautionary measures when visiting health care facilities. In the present study, it is assumed that, if LA-MRSA was introduced to the Swedish pig population, the prevalence in the risk groups would be the same as in Denmark or the Netherlands (two countries with low human prevalence that have implemented measures to detect, trace and isolate human LA-MRSA cases and, therefore, have comprehensive data with good coverage regarding prevalence of LA-MRSA), and that similar interventions would be taken in Swedish health care facilities. It is also assumed that the Swedish pig population is free of MRSA or that the prevalence is very low. We analyse if it would be efficient for Sweden to prevent its introduction by testing imported live breeding pigs. Given that quarantining and testing at import will prevent introduction to the pig population, the study shows that the preventive measures may indeed generate a societal net benefit. Benefits are estimated to be between (sic) 870 720 and (sic) 1 233 511, and costs to (sic) 211 129. Still, due to gaps in knowledge, the results should be confirmed when more information become available.
OriginalspråkEngelska
Artikelnummere.0122875
Antal sidor22
TidskriftPLOS ONE
Volym10
Nummer4
DOI
StatusPublicerad - 2015

FN:s SDG:er

Detta resultat bidrar till följande hållbara utvecklingsmål:

  1. SDG 3 – God hälsa och välbefinnande
    SDG 3 – God hälsa och välbefinnande

Nyckelord

  • Antibiotic resistance Prevention Cost benefit

Citera det här